After-Hours Stock Movers 11/09: (SHAK) (OMER) (TASR) Higher; (HLIT) (AVID) (TWTR) Lower (more...)

November 9, 2016 6:34 PM EST

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Today's After-Hours Movers

Harmonic (NASDAQ: HLIT) 19.1% LOWER; reported Q3 EPS of ($0.01), $0.04 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $101.4 million versus the consensus estimate of $107.24 million. GUIDANCE: Harmonic sees Q4 2016 EPS of $5.00-$0.07, versus the consensus of $0.13. Harmonic sees Q4 2016 revenue of $105.8-110.8 million, versus the consensus of $116.1 million.

Avid Technology (NASDAQ: AVID) 16.6% LOWER; reported Q3 EPS of $0.23, $0.19 worse than the analyst estimate of $0.42. Revenue for the quarter came in at $119 million versus the consensus estimate of $130.62 million. GUIDANCE: Avid Technology sees FY2016 revenue of $105-120 million, versus the consensus of $139.4 million. Avid Technology sees FY2016 revenue of $502-517 million, versus the consensus of $547.9 million.

Trovagene (NASDAQ: TROV) 15.2% LOWER; reported Q3 EPS of ($0.34), $0.01 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $89 thousand versus the consensus estimate of $320 thousand.

Novavax (NASDAQ: NVAX) 12.9% LOWER; reported Q3 EPS of ($0.24), $0.02 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.02 million.

Rapid7, Inc. (NASDAQ: RPD) 10% LOWER; reported Q3 EPS of ($0.13), $0.07 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $40.3 million versus the consensus estimate of $39.42 million. GUIDANCE: Rapid7, Inc. sees Q4 2016 EPS of ($0.28)-($0.26), versus the consensus of ($0.24). Rapid7, Inc. sees Q4 2016 revenue of $42.2-43.6 million, versus the consensus of $43.3 million. Rapid7, Inc. sees FY2016 EPS of ($0.87)-($0.84), versus the consensus of ($0.91). Rapid7, Inc. sees FY2016 revenue of $154.6-156.0 million, versus the consensus of $154.7 million.

Shake Shack (NYSE: SHAK) 9.6% HIGHER; reported Q3 EPS of $0.15, $0.01 better than the analyst estimate of $0.14. Revenue for the quarter came in at $74.6 million versus the consensus estimate of $69.33 million. Same-Shack sales increased 2.9%. GUIDANCE: Shake Shack sees FY2016 revenue of $264-265 million, versus the consensus of $258.55 million. Shake Shack sees FY2016 revenue of $348-352 million, versus the consensus of $335.4 million.

Omeros (NASDAQ: OMER) 8.1% HIGHER; reported Q3 EPS of ($0.34), $0.06 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $11.3 million versus the consensus estimate of $11.64 million.

TASER Int'l (NASDAQ: TASR) 8.1% HIGHER; reported Q3 EPS of $0.07, $0.01 better than the analyst estimate of $0.06. Revenue for the quarter came in at $71.9 million versus the consensus estimate of $59 million. TASER also announced today that following a transition period, CFO Dan Behrendt will be leaving the Company to pursue other opportunities.

CSRA, Inc. (NYSE: CSRA) 7.7% HIGHER; reported Q2 EPS of $0.56, $0.10 better than the analyst estimate of $0.46. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.24 billion.

ZELTIQ Aesthetics (NASDAQ: ZLTQ) 7.6% HIGHER; reported Q3 EPS of $0.12, $0.04 better than the analyst estimate of $0.08. Revenue for the quarter came in at $95.2 million versus the consensus estimate of $90.56 million. On a non-GAAP basis, the company reported adjusted EBITDA of $16.6 million, or 17.4% of revenue, for the third quarter 2016, compared to $5.6 million, or 9.2% of revenue, for the third quarter 2015. GUIDANCE: ZELTIQ Aesthetics sees FY2016 revenue of $352-352 million, versus prior guidance of $340-350 million/

Bovie Medical Corporation (NYST: BVX) 5.8% LOWER announced today that the Company and certain selling stockholders intend to offer shares of the Companys common stock in concurrent public offerings. Bovie Medical and the selling stockholders also expect to grant the underwriters a 30-day option to purchase additional shares of its common stock to cover over-allotments, if any. Bovie Medical will use the net proceeds from the offering to expand its sales and marketing activities, to expand its research and development efforts, to conduct clinical trials, and for general corporate purposes and working capital. The Company will not receive any proceeds from the sale of common stock by the selling stockholders.

SolarEdge Technologies (NASDAQ: SEDG) 5% LOWER; reported Q1 EPS of $0.46, $0.02 better than the analyst estimate of $0.44. Revenue for the quarter came in at $128.5 million versus the consensus estimate of $132.28 million. GUIDANCE: SolarEdge Technologies sees Q2 2017 revenue of $110-120 million, versus the consensus of $136.91 million.

Merrimack Pharma (NASDAQ: MACK) 5.3% LOWER; reported Q3 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $28.07 million versus the consensus estimate of $39.2 million.

U.S. Silica Holdings, Inc. (NYSE: SLCA) 4% LOWER; announced today that it has commenced an underwritten public offering of 9,000,000 shares of U.S. Silica common stock.

Twitter, Inc. (NYSE: TWTR) 2.6% LOWER; announced that Adam Bain has informed the company of his decision to step down as COO and explore opportunities outside the company. Anthony Noto who has served as the Company's Chief Financial Officer since July, 2014, has been named COO. As COO he will continue to manage the live content business, and assume responsibility for Twitter's revenue generating organizations including global advertising sales, data, revenue product, and MoPub, as well as global partnerships and business development, effective immediately. Bain will assist with the transition of the COO role over the coming weeks.

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) 2.5% LOWER; announced that it has filed with the U.S. Securities and Exchange Commission (SEC) a Form 12b-25 Notification of Late Filing with regard to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. The Audit and Finance Committee of the Board of Directors is conducting an investigation into allegations that recently have been made by a former employee with respect to the Company’s sales practices of Soliris® (eculizumab). Specifically, the Audit and Finance Committee is investigating whether Company personnel have engaged in sales practices that were inconsistent with Company policies and procedures and the related disclosure and other considerations raised by such practices. The Audit and Finance Committee has retained outside counsel to assist it in the investigation.

Mylan (NASDAQ: MYL) 2.4% LOWER; reported Q3 EPS of $1.38, $0.08 worse than the analyst estimate of $1.46. Revenue for the quarter came in at $3.06 billion versus the consensus estimate of $3.12 billion.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Twitter, After-Hours Movers

Add Your Comment